PUBLISHER: Market Xcel - Markets and Data | PRODUCT CODE: 1718947
PUBLISHER: Market Xcel - Markets and Data | PRODUCT CODE: 1718947
HIV Drugs Market Assessment, By Drug Class, By Major Brands, By Distribution Channel, By Region, Opportunities and Forecast, 2018-2032F
Global HIV drugs market is projected to witness a CAGR of 4.21% during the forecast period 2025-2032, growing from USD 35.83 billion in 2024 to USD 49.83 billion in 2032. Increasing prevalence of HIV/AIDS, rising efforts of different governments to increase awareness about the condition, and growing awareness about the various treatment solutions available are some of the major factors driving the growth of the market. The World Health Organization estimates that approximately 39.9 million people across the globe were living with HIV by the end of 2023 of which 38.6 million were above the age of 15, while 1.4 million were 14 and younger.
HIV drug therapies include a wide array of antiretroviral medications designed to reduce viral load, boost immune function, and prevent HIV transmission. These drugs are critical for prolonging the life expectancy for HIV-positive individuals and in ensuring a better quality of life by managing symptoms and minimizing the risk of opportunistic infections.
Supportive Regulatory Initiatives Boost Market Growth
Supportive government policies and regulatory initiatives such as priority review incentivize leading market players and pharmaceutical companies to focus on product innovation and introduction of new technologies. Regulatory agencies such as the FDA and EMA are expediting drug approvals, particularly for innovative therapies such as long-acting injectables and fixed-dose combinations, ensuring that patients benefit from the latest advancements. For instance, in February 2025, Gilead Sciences, Inc. received approval from the US FDA for its New Drug Application (NDA) submission for lenacapavir, its injectable HIV-1 capsid inhibitor, indicated for the prevention of HIV as pre-exposure prophylaxis (PrEP). Furthermore, these agencies also facilitate the introduction of generics following the expiration of the patents, which increases competition, increases the affordability of the drugs, and improves their accessibility. Additionally, public health campaigns, early diagnosis initiatives, and insurance coverage reforms are raising awareness and reducing stigma about HIV infections, further driving the market's growth and expansion.
Strategic Partnerships and Collaborations Support Market Expansion
The key players of the market are heavily investing in research and development activities to develop safer and more effective treatments for HIV, targeting drug resistance and focusing on reducing long-term side effects. The shift toward long-acting formulations, including cabotegravir and rilpivirine injectables, exemplifies innovation aimed at improving adherence.
Moreover, strategic collaborations between public and private entities are streamlining drug approval and distribution processes and ensuring the affordability and accessibility of the medications. For instance, in October 2024, Gilead Sciences, Inc. signed a royalty-free and non-exclusive voluntary licensing agreement with six leading pharmaceutical manufacturers to sell and manufacture generic lenacapavir. The agreement also covers HIV treatment in adults with multi-drug-resistant HIV.
Additionally, in Africa and Asia, local production is increasingly supported by international partnerships, strengthening regional resilience and improving treatment access. Furthermore, digital health platforms and mobile clinics are being leveraged to extend patient monitoring and medication adherence support in remote areas. These technology-driven interventions are enhancing treatment efficacy and facilitating real-time health data collection, contributing to improved patient outcomes and rapid market growth.
Hospitals Pharmacies Account for Significant Share of the Market
The segment's dominance can be attributed to the central role played by hospitals in comprehensive treatment and management of HIV/AIDS. Hospital pharmacies provide counselling, close monitoring of the condition, and specialized medication management, which are essential for minimizing drug interactions, adjusting regimens, and optimizing adherence for complex cases. Additionally, the direct collaboration between hospital pharmacies and healthcare providers further allows for integrated care and provision of tailored therapy solutions, improving treatment outcomes.
Furthermore, leading hospital pharmacies across the globe are focusing on expanding their market presence, further contributing to the segment's growth. For instance, in March 2025, Apollo HealthCo Ltd, operator of Apollo Pharmacy and online platform Apollo 24/7, announced expansion of its offline pharmacy network in Bengal, India.
North America Holds Major Market Share
North America is expected to hold a significant share of the market in the coming years owing to the rising prevalence of HIV infections, increasing awareness among the general population, and the strong presence of leading pharmaceutical companies in the region. Additionally, the presence of robust healthcare systems in the regions ensures broad access to cutting-edge medications and healthcare technologies, while government initiatives such as the Ryan White HIV/AIDS Program and the Ending the HIV Epidemic plan subsidize treatment costs, improve the accessibility of HIV drugs, especially for vulnerable populations.
Meanwhile, the Asia-Pacific is expected to witness rapid growth over the forecast period owing to rapid population expansion, increasing efforts of leading pharmaceutical companies to bolster the availability of advanced therapeutic solutions in the region, and growing awareness among the population. Leading organizations are also joining forces to combat the growing threat of HIV infection in the region, providing lucrative growth opportunities for the market. For instance, in April 2025, the UNICEF, UNAIDS, and WHO launched the Regional Roadmap for the Triple Elimination of Mother-to-Child Transmission (EMTCT) of Syphilis, HIV, and Hepatitis B in the Asia-Pacific Region (2024-2030).
Impact of the U.S. Tariff on Global HIV Drugs Market
The recently introduced tariffs are expected to disrupt supply chains and impact the availability of antiretroviral therapies and reduce their affordability. Indian generic drug manufacturers are also expected to observe financial strains because of the tariffs as these manufacturers operate on thin margins, potentially forcing them to withdraw from the market in the United States. Additionally, various manufacturers across the globe might need to restructure their operations and move their manufacturing units to avoid tariffs, resulting in potential delays in drug availability. Such delays are particularly detrimental for HIV positive patients as medication adherence is crucial for managing the condition.
Key Players Landscape and Outlook
The key players of the market are focusing on receiving approvals from different regulatory and governing bodies across the globe to market and distribute their HIV drugs. For instance, in February 2023 ViiV Healthcare, a subsidiary of GlaxoSmithKline plc, received marketing authorization for Triumeq from the European Commission. By providing child-friendly dispersible tablets and lowering the minimum weight for Triumeq's administration, ViiV is aiding healthcare professionals in improving viral suppression rates and treatment adherence among younger patients. Such approvals support innovations and inclusivity in HIV therapy, encouraging leading market players and pharmaceutical companies to develop pediatric formulations, ensuring that the underserved patient population is provided with viable treatment solutions, providing lucrative growth opportunities for the market.
Table of Contents
1. Project Scope and Definitions
2. Research Methodology
3. Impact of the U.S. Tariffs
4. Executive Summary
5. Global HIV Drugs Market Outlook, 2018-2032F
- 5.1. Market Size Analysis & Forecast
- 5.1.1. By Value
- 5.2. Market Share Analysis & Forecast
- 5.2.1. By Drug Class
- 5.2.1.1. Integrase Inhibitors
- 5.2.1.2. Non- Nucleoside Reverse Transcriptase Inhibitors (NRTIs)
- 5.2.1.3. Combination HIV Medicines
- 5.2.1.4. Other
- 5.2.2. By Major Brands
- 5.2.2.1. Biktarvy
- 5.2.2.2. Dovato
- 5.2.2.3. Genvoya
- 5.2.2.4. Descovy
- 5.2.2.5. Triumeq
- 5.2.2.6. Prezista
- 5.2.2.7. Tivicay
- 5.2.2.8. Odefsey
- 5.2.2.9. Others
- 5.2.3. By Distribution Channel
- 5.2.3.1. Hospital Pharmacies
- 5.2.3.2. Retail Pharmacies
- 5.2.3.3. Online Pharmacies
- 5.2.4. By Region
- 5.2.4.1. North America
- 5.2.4.2. Europe
- 5.2.4.3. Asia-Pacific
- 5.2.4.4. South America
- 5.2.4.5. Middle East and Africa
- 5.2.5. By Company Market Share Analysis (Top 5 Companies and Others - By Value, 2024)
- 5.2.1. By Drug Class
- 5.3. Market Map Analysis, 2024
- 5.3.1. By Drug Class
- 5.3.2. By Major Brands
- 5.3.3. By Distribution Channel
- 5.3.4. By Region
6. North America HIV Drugs Market Outlook, 2018-2032F
- 6.1. Market Size Analysis & Forecast
- 6.1.1. By Value
- 6.2. Market Share Analysis & Forecast
- 6.2.1. By Drug Class
- 6.2.1.1. Integrase Inhibitors
- 6.2.1.2. Non- Nucleoside Reverse Transcriptase Inhibitors (NRTIs)
- 6.2.1.3. Combination HIV Medicines
- 6.2.1.4. Other
- 6.2.2. By Major Brands
- 6.2.2.1. Biktarvy
- 6.2.2.2. Dovato
- 6.2.2.3. Genvoya
- 6.2.2.4. Descovy
- 6.2.2.5. Triumeq
- 6.2.2.6. Prezista
- 6.2.2.7. Tivicay
- 6.2.2.8. Odefsey
- 6.2.2.9. Others
- 6.2.3. By Distribution Channel
- 6.2.3.1. Hospital Pharmacies
- 6.2.3.2. Retail Pharmacies
- 6.2.3.3. Online Pharmacies
- 6.2.4. By Country Share
- 6.2.4.1. United States
- 6.2.4.2. Canada
- 6.2.4.3. Mexico
- 6.2.1. By Drug Class
- 6.3. Country Market Assessment
- 6.3.1. United States HIV Drugs Market Outlook, 2018-2032F*
- 6.3.1.1. Market Size Analysis & Forecast
- 6.3.1.1.1. By Value
- 6.3.1.2. Market Share Analysis & Forecast
- 6.3.1.2.1. By Drug Class
- 6.3.1.2.1.1. Integrase Inhibitors
- 6.3.1.2.1.2. Non- Nucleoside Reverse Transcriptase Inhibitors (NRTIs)
- 6.3.1.2.1.3. Combination HIV Medicines
- 6.3.1.2.1.4. Other
- 6.3.1.2.2. By Major Brands
- 6.3.1.2.2.1. Biktarvy
- 6.3.1.2.2.2. Dovato
- 6.3.1.2.2.3. Genvoya
- 6.3.1.2.2.4. Descovy
- 6.3.1.2.2.5. Triumeq
- 6.3.1.2.2.6. Prezista
- 6.3.1.2.2.7. Tivicay
- 6.3.1.2.2.8. Odefsey
- 6.3.1.2.2.9. Others
- 6.3.1.2.3. By Distribution Channel
- 6.3.1.2.3.1. Hospital Pharmacies
- 6.3.1.2.3.2. Retail Pharmacies
- 6.3.1.2.3.3. Online Pharmacies
- 6.3.1.2.1. By Drug Class
- 6.3.1.1. Market Size Analysis & Forecast
- 6.3.2. Canada
- 6.3.3. Mexico
- 6.3.1. United States HIV Drugs Market Outlook, 2018-2032F*
All segments will be provided for all regions and countries covered
7. Europe HIV Drugs Market Outlook, 2018-2032F
- 7.1. Germany
- 7.2. France
- 7.3. Italy
- 7.4. United Kingdom
- 7.5. Russia
- 7.6. Netherlands
- 7.7. Spain
- 7.8. Turkey
- 7.9. Poland
8. Asia-Pacific HIV Drugs Market Outlook, 2018-2032F
- 8.1. India
- 8.2. China
- 8.3. Japan
- 8.4. Australia
- 8.5. Vietnam
- 8.6. South Korea
- 8.7. Indonesia
- 8.8. Philippines
9. South America HIV Drugs Market Outlook, 2018-2032F
- 9.1. Brazil
- 9.2. Argentina
10. Middle East and Africa HIV Drugs Market Outlook, 2018-2032F
- 10.1. Saudi Arabia
- 10.2. UAE
- 10.3. South Africa
11. Demand Supply Analysis
12. Value Chain Analysis
13. Porter's Five Forces Analysis
14. PESTLE Analysis
15. Pricing Analysis
16. Market Dynamics
- 16.1. Market Drivers
- 16.2. Market Challenges
17. Market Trends and Developments
18. Regulatory Framework and Innovation
- 18.1. Regulatory Approvals
- 18.2. Clinical Trials
19. Patent Landscape
20. Case Studies
21. Competitive Landscape
- 21.1. Competition Matrix of Top 5 Market Leaders
- 21.2. SWOT Analysis for Top 5 Players
- 21.3. Key Players Landscape for Top 10 Market Players
- 21.3.1. Gilead Sciences, Inc.
- 21.3.1.1. Company Details
- 21.3.1.2. Key Management Personnel
- 21.3.1.3. Products and Services
- 21.3.1.4. Financials (As Reported)
- 21.3.1.5. Key Market Focus and Geographical Presence
- 21.3.1.6. Recent Developments/Collaborations/Partnerships/Mergers and Acquisition
- 21.3.2. GlaxoSmithKline plc
- 21.3.3. Bristol-Myers Squibb Company
- 21.3.4. Johnson & Johnson Services, Inc.
- 21.3.5. Teva Pharmaceutical Industries Ltd.
- 21.3.6. Cipla Ltd.
- 21.3.7. AbbVie Inc.
- 21.3.8. Boehringer Ingelheim International GmbH
- 21.3.9. Merck & Co., Inc.
- 21.3.10. F. Hoffmann-La Roche Ltd.
- 21.3.1. Gilead Sciences, Inc.
Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.
22. Strategic Recommendations
23. About Us and Disclaimer
List of Tables
- Table 1. Competition Matrix of Top 5 Market Leaders
- Table 2. Mergers & Acquisitions/ Joint Ventures (If Applicable)
- Table 3. About Us - Regions and Countries Where We Have Executed Client Projects
List of Figures
- Figure 1. Global HIV Drugs Market, By Value, In USD Billion, 2018-2032F
- Figure 2. Global HIV Drugs Market Share (%), By Drug Class, 2018-2032F
- Figure 3. Global HIV Drugs Market Share (%), By Major Brands, 2018-2032F
- Figure 4. Global HIV Drugs Market Share (%), By Distribution Channel, 2018-2032F
- Figure 5. Global HIV Drugs Market Share (%), By Region, 2018-2032F
- Figure 6. North America HIV Drugs Market, By Value, In USD Billion, 2018-2032F
- Figure 7. North America HIV Drugs Market Share (%), By Drug Class, 2018-2032F
- Figure 8. North America HIV Drugs Market Share (%), By Major Brands, 2018-2032F
- Figure 9. North America HIV Drugs Market Share (%), By Distribution Channel, 2018-2032F
- Figure 10. North America HIV Drugs Market Share (%), By Country, 2018-2032F
- Figure 11. United States HIV Drugs Market, By Value, In USD Billion, 2018-2032F
- Figure 12. United States HIV Drugs Market Share (%), By Drug Class, 2018-2032F
- Figure 13. United States HIV Drugs Market Share (%), By Major Brands, 2018-2032F
- Figure 14. United States HIV Drugs Market Share (%), By Distribution Channel, 2018-2032F
- Figure 15. Canada HIV Drugs Market, By Value, In USD Billion, 2018-2032F
- Figure 16. Canada HIV Drugs Market Share (%), By Drug Class, 2018-2032F
- Figure 17. Canada HIV Drugs Market Share (%), By Major Brands, 2018-2032F
- Figure 18. Canada HIV Drugs Market Share (%), By Distribution Channel, 2018-2032F
- Figure 19. Mexico HIV Drugs Market, By Value, In USD Billion, 2018-2032F
- Figure 20. Mexico HIV Drugs Market Share (%), By Drug Class, 2018-2032F
- Figure 21. Mexico HIV Drugs Market Share (%), By Major Brands, 2018-2032F
- Figure 22. Mexico HIV Drugs Market Share (%), By Distribution Channel, 2018-2032F
- Figure 23. Europe HIV Drugs Market, By Value, In USD Billion, 2018-2032F
- Figure 24. Europe HIV Drugs Market Share (%), By Drug Class, 2018-2032F
- Figure 25. Europe HIV Drugs Market Share (%), By Major Brands, 2018-2032F
- Figure 26. Europe HIV Drugs Market Share (%), By Distribution Channel, 2018-2032F
- Figure 27. Europe HIV Drugs Market Share (%), By Country, 2018-2032F
- Figure 28. Germany HIV Drugs Market, By Value, In USD Billion, 2018-2032F
- Figure 29. Germany HIV Drugs Market Share (%), By Drug Class, 2018-2032F
- Figure 30. Germany HIV Drugs Market Share (%), By Major Brands, 2018-2032F
- Figure 31. Germany HIV Drugs Market Share (%), By Distribution Channel, 2018-2032F
- Figure 32. France HIV Drugs Market, By Value, In USD Billion, 2018-2032F
- Figure 33. France HIV Drugs Market Share (%), By Drug Class, 2018-2032F
- Figure 34. France HIV Drugs Market Share (%), By Major Brands, 2018-2032F
- Figure 35. France HIV Drugs Market Share (%), By Distribution Channel, 2018-2032F
- Figure 36. Italy HIV Drugs Market, By Value, In USD Billion, 2018-2032F
- Figure 37. Italy HIV Drugs Market Share (%), By Drug Class, 2018-2032F
- Figure 38. Italy HIV Drugs Market Share (%), By Major Brands, 2018-2032F
- Figure 39. Italy HIV Drugs Market Share (%), By Distribution Channel, 2018-2032F
- Figure 40. United Kingdom HIV Drugs Market, By Value, In USD Billion, 2018-2032F
- Figure 41. United Kingdom HIV Drugs Market Share (%), By Drug Class, 2018-2032F
- Figure 42. United Kingdom HIV Drugs Market Share (%), By Major Brands, 2018-2032F
- Figure 43. United Kingdom HIV Drugs Market Share (%), By Distribution Channel, 2018-2032F
- Figure 44. Russia HIV Drugs Market, By Value, In USD Billion, 2018-2032F
- Figure 45. Russia HIV Drugs Market Share (%), By Drug Class, 2018-2032F
- Figure 46. Russia HIV Drugs Market Share (%), By Major Brands, 2018-2032F
- Figure 47. Russia HIV Drugs Market Share (%), By Distribution Channel, 2018-2032F
- Figure 48. Netherlands HIV Drugs Market, By Value, In USD Billion, 2018-2032F
- Figure 49. Netherlands HIV Drugs Market Share (%), By Drug Class, 2018-2032F
- Figure 50. Netherlands HIV Drugs Market Share (%), By Major Brands, 2018-2032F
- Figure 51. Netherlands HIV Drugs Market Share (%), By Distribution Channel, 2018-2032F
- Figure 52. Spain HIV Drugs Market, By Value, In USD Billion, 2018-2032F
- Figure 53. Spain HIV Drugs Market Share (%), By Drug Class, 2018-2032F
- Figure 54. Spain HIV Drugs Market Share (%), By Major Brands, 2018-2032F
- Figure 55. Spain HIV Drugs Market Share (%), By Distribution Channel, 2018-2032F
- Figure 56. Turkey HIV Drugs Market, By Value, In USD Billion, 2018-2032F
- Figure 57. Turkey HIV Drugs Market Share (%), By Drug Class, 2018-2032F
- Figure 58. Turkey HIV Drugs Market Share (%), By Major Brands, 2018-2032F
- Figure 59. Turkey HIV Drugs Market Share (%), By Distribution Channel, 2018-2032F
- Figure 60. Poland HIV Drugs Market, By Value, In USD Billion, 2018-2032F
- Figure 61. Poland HIV Drugs Market Share (%), By Drug Class, 2018-2032F
- Figure 62. Poland HIV Drugs Market Share (%), By Major Brands, 2018-2032F
- Figure 63. Poland HIV Drugs Market Share (%), By Distribution Channel, 2018-2032F
- Figure 64. South America HIV Drugs Market, By Value, In USD Billion, 2018-2032F
- Figure 65. South America HIV Drugs Market Share (%), By Drug Class, 2018-2032F
- Figure 66. South America HIV Drugs Market Share (%), By Major Brands, 2018-2032F
- Figure 67. South America HIV Drugs Market Share (%), By Distribution Channel, 2018-2032F
- Figure 68. South America HIV Drugs Market Share (%), By Country, 2018-2032F
- Figure 69. Brazil HIV Drugs Market, By Value, In USD Billion, 2018-2032F
- Figure 70. Brazil HIV Drugs Market Share (%), By Drug Class, 2018-2032F
- Figure 71. Brazil HIV Drugs Market Share (%), By Major Brands, 2018-2032F
- Figure 72. Brazil HIV Drugs Market Share (%), By Distribution Channel, 2018-2032F
- Figure 73. Argentina HIV Drugs Market, By Value, In USD Billion, 2018-2032F
- Figure 74. Argentina HIV Drugs Market Share (%), By Drug Class, 2018-2032F
- Figure 75. Argentina HIV Drugs Market Share (%), By Major Brands, 2018-2032F
- Figure 76. Argentina HIV Drugs Market Share (%), By Distribution Channel, 2018-2032F
- Figure 77. Asia-Pacific HIV Drugs Market, By Value, In USD Billion, 2018-2032F
- Figure 78. Asia-Pacific HIV Drugs Market Share (%), By Drug Class, 2018-2032F
- Figure 79. Asia-Pacific HIV Drugs Market Share (%), By Major Brands, 2018-2032F
- Figure 80. Asia-Pacific HIV Drugs Market Share (%), By Distribution Channel, 2018-2032F
- Figure 81. Asia-Pacific HIV Drugs Market Share (%), By Country, 2018-2032F
- Figure 82. India HIV Drugs Market, By Value, In USD Billion, 2018-2032F
- Figure 83. India HIV Drugs Market Share (%), By Drug Class, 2018-2032F
- Figure 84. India HIV Drugs Market Share (%), By Major Brands, 2018-2032F
- Figure 85. India HIV Drugs Market Share (%), By Distribution Channel, 2018-2032F
- Figure 86. China HIV Drugs Market, By Value, In USD Billion, 2018-2032F
- Figure 87. China HIV Drugs Market Share (%), By Drug Class, 2018-2032F
- Figure 88. China HIV Drugs Market Share (%), By Major Brands, 2018-2032F
- Figure 89. China HIV Drugs Market Share (%), By Distribution Channel, 2018-2032F
- Figure 90. Japan HIV Drugs Market, By Value, In USD Billion, 2018-2032F
- Figure 91. Japan HIV Drugs Market Share (%), By Drug Class, 2018-2032F
- Figure 92. Japan HIV Drugs Market Share (%), By Major Brands, 2018-2032F
- Figure 93. Japan HIV Drugs Market Share (%), By Distribution Channel, 2018-2032F
- Figure 94. Australia HIV Drugs Market, By Value, In USD Billion, 2018-2032F
- Figure 95. Australia HIV Drugs Market Share (%), By Drug Class, 2018-2032F
- Figure 96. Australia HIV Drugs Market Share (%), By Major Brands, 2018-2032F
- Figure 97. Australia HIV Drugs Market Share (%), By Distribution Channel, 2018-2032F
- Figure 98. Vietnam HIV Drugs Market, By Value, In USD Billion, 2018-2032F
- Figure 99. Vietnam HIV Drugs Market Share (%), By Drug Class, 2018-2032F
- Figure 100. Vietnam HIV Drugs Market Share (%), By Major Brands, 2018-2032F
- Figure 101. Vietnam HIV Drugs Market Share (%), By Distribution Channel, 2018-2032F
- Figure 102. South Korea HIV Drugs Market, By Value, In USD Billion, 2018-2032F
- Figure 103. South Korea HIV Drugs Market Share (%), By Drug Class, 2018-2032F
- Figure 104. South Korea HIV Drugs Market Share (%), By Major Brands, 2018-2032F
- Figure 105. South Korea HIV Drugs Market Share (%), By Distribution Channel, 2018-2032F
- Figure 106. Indonesia HIV Drugs Market, By Value, In USD Billion, 2018-2032F
- Figure 107. Indonesia HIV Drugs Market Share (%), By Drug Class, 2018-2032F
- Figure 108. Indonesia HIV Drugs Market Share (%), By Major Brands, 2018-2032F
- Figure 109. Indonesia HIV Drugs Market Share (%), By Distribution Channel, 2018-2032F
- Figure 110. Philippines HIV Drugs Market, By Value, In USD Billion, 2018-2032F
- Figure 111. Philippines HIV Drugs Market Share (%), By Drug Class, 2018-2032F
- Figure 112. Philippines HIV Drugs Market Share (%), By Major Brands, 2018-2032F
- Figure 113. Philippines HIV Drugs Market Share (%), By Distribution Channel, 2018-2032F
- Figure 114. Middle East & Africa HIV Drugs Market, By Value, In USD Billion, 2018-2032F
- Figure 115. Middle East & Africa HIV Drugs Market Share (%), By Drug Class, 2018-2032F
- Figure 116. Middle East & Africa HIV Drugs Market Share (%), By Major Brands, 2018-2032F
- Figure 117. Middle East & Africa HIV Drugs Market Share (%), By Distribution Channel, 2018-2032F
- Figure 118. Middle East & Africa HIV Drugs Market Share (%), By Country, 2018-2032F
- Figure 119. Saudi Arabia HIV Drugs Market, By Value, In USD Billion, 2018-2032F
- Figure 120. Saudi Arabia HIV Drugs Market Share (%), By Drug Class, 2018-2032F
- Figure 121. Saudi Arabia HIV Drugs Market Share (%), By Major Brands, 2018-2032F
- Figure 122. Saudi Arabia HIV Drugs Market Share (%), By Distribution Channel, 2018-2032F
- Figure 123. UAE HIV Drugs Market, By Value, In USD Billion, 2018-2032F
- Figure 124. UAE HIV Drugs Market Share (%), By Drug Class, 2018-2032F
- Figure 125. UAE HIV Drugs Market Share (%), By Major Brands, 2018-2032F
- Figure 126. UAE HIV Drugs Market Share (%), By Distribution Channel, 2018-2032F
- Figure 127. South Africa HIV Drugs Market, By Value, In USD Billion, 2018-2032F
- Figure 128. South Africa HIV Drugs Market Share (%), By Drug Class, 2018-2032F
- Figure 129. South Africa HIV Drugs Market Share (%), By Major Brands, 2018-2032F
- Figure 130. South Africa HIV Drugs Market Share (%), By Distribution Channel, 2018-2032F
- Figure 131. By Drug Class Map-Market Size (USD Billion) & Growth Rate (%), 2024
- Figure 132. By Major Brands Map-Market Size (USD Billion) & Growth Rate (%), 2024
- Figure 133. By Distribution Channel Map-Market Size (USD Billion) & Growth Rate (%), 2024
- Figure 134. By Region Map-Market Size (USD Billion) & Growth Rate (%), 2024
